NEWFlashcards for any set of questions, quick-reference tables for breast, lung and prostate, and a month of access for every colleague you refer. See what changed

Head & neck: Salivary gland — postoperative radiotherapy indications

Free question published 09 November 2026

Head & neckSalivary gland — postoperative radiotherapy indications

A 57-year-old woman has a superficial parotidectomy with facial nerve preservation for adenoid cystic carcinoma. Histology shows a closest margin of 2 mm and extensive perineural invasion, including a named branch of the facial nerve. Staging imaging shows no nodal or distant disease. What is the most appropriate adjuvant management?

  1. ASurveillance with MRI
  2. BRadiotherapy to the parotid bed
  3. CRadiotherapy to the parotid bed and facial nerve pathway
  4. DCisplatin-radiotherapy to the parotid bed and facial nerve pathway
  5. EAdjuvant cisplatin, doxorubicin and cyclophosphamide

Why C is correct

Adenoid cystic carcinoma is itself a specific consideration for postoperative radiotherapy in the UK guideline, and a close margin and perineural invasion are adverse features for which ASCO advises postoperative radiotherapy. Because the perineural invasion is extensive and involves a named nerve, the volume should include the affected nerve pathway as well as the parotid bed (SFRO 2025 update; ASCO notes the volume may be extended along the nerve pathway in this situation). Concurrent or adjuvant chemotherapy is not established after resection of salivary gland cancer.

And why the others are not

  • AWrong — adenoid cystic carcinoma with a close margin and perineural invasion meets recognised indications for postoperative radiotherapy, which improved survival in a large US National Cancer Database analysis cited by the UK guideline.
  • BWrong — the bed alone would leave out the involved nerve; with extensive perineural invasion, particularly in adenoid cystic carcinoma, inclusion of the affected nerve pathway in the radiotherapy field is advised.
  • DWrong — concurrent chemotherapy did not improve outcome in the National Cancer Database analysis cited by the UK guideline, and ASCO does not recommend routine adjuvant systemic therapy outside a trial.
  • EWrong — routine adjuvant systemic chemotherapy is not recommended outside a clinical trial after resection of salivary gland malignancy.

Source Management of Salivary Gland Malignancy — ASCO Guideline — Geiger JL, Ismaila N, Beadle B, et al. J Clin Oncol 2021;39(17):1909-1941. DOI 10.1200/JCO.21.00449.

Sitting in February? Follow the twenty-week plan.

2,500+ cited questions like this one are waiting in the vault.

See plans and pricing